{"analyses":[{"ciLowerLimit":"1.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.39","estimateComment":"The odds ratio and 95% CI were calculated using a stratified CMH test.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The one-sided p-value was calculated using a stratified Cochran-Mantel-Haenszel (CMH) test.","paramType":"Odds Ratio (OR)","paramValue":"2.77","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.6","upperLimit":"62.3","value":"54.5"},{"groupId":"OG001","lowerLimit":"24.1","upperLimit":"38.8","value":"31.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants in each arm demonstrating a CR or PR based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response. Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"Cycle 4 Day 1 (each cycle was comprised of 4 weeks)","title":"ORR at the End of Cycle 3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}